Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis

2010 ◽  
Vol 2010 ◽  
pp. 77-80
Author(s):  
P.P. Toth
Keyword(s):  
Heart Failure ◽  
Statin Therapy ◽  
Retrospective Analysis ◽  
Protein Concentration ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Multinational Trial

scholarly journals High Sensitivity C-Reactive Protein Predicts Nonresponders and Cardiac Deaths in Severe Heart Failure Patients After CRT Implantation

2012 ◽  
Vol 53 (5) ◽  
pp. 306-312 ◽  
Author(s):  
Masashi Kamioka ◽  
Hitoshi Suzuki ◽  
Shinya Yamada ◽  
Yoshiyuki Kamiyama ◽  
Shu-ichi Saitoh ◽  
...  
Keyword(s):  
Heart Failure ◽  
Severe Heart Failure ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Heart Failure Patients ◽  
Reactive Protein

scholarly journals The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation

2014 ◽  
Vol 25 (4) ◽  
pp. 409-418 ◽  
Author(s):  
Corinne E. Joshu ◽  
Kostantinos K. Tsilidis ◽  
Sarah B. Peskoe ◽  
Francis M. Giardiello ◽  
Paul J. Dluzniewski ◽  
...  
Keyword(s):  
Protein Concentration ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Colonic Inflammation ◽  
Reactive Protein

scholarly journals Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy

2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Myung Han Hyun ◽  
Yuchang Lee ◽  
Byoung Geol Choi ◽  
Jin Oh Na ◽  
Cheol Ung Choi ◽  
...  
Keyword(s):  
Statin Therapy ◽  
De Novo ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
High Sensitivity ◽  
Cardiovascular Outcome ◽  
Low Density ◽  
C Reactive Protein ◽  
Low Density Lipoprotein Cholesterol ◽  
Reactive Protein

In statin therapy, the prognostic role of achieved low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP) in cardiovascular outcomes has not been fully elucidated. A total of 4,803 percutaneous coronary intervention (PCI)-naïve patients who prescribed moderate intensity of statin therapy were followed up. Total and each component of major adverse cardiovascular events (MACE) according to LDL-C and hsCRP quartiles were compared. The incidence of 5-year total MACEs in the highest quartile group according to the followed-up hsCRP was higher than that in the lowest quartile (hazard ratio (HR) = 2.16, p<0.001). However, there was no difference between the highest and lowest quartiles of the achieved LDL-C (HR = 0.95, p=0.743). After adjustment of potential confounders, the incidence of total death, de novo PCI, atrial fibrillation, and heart failure in the highest quartile of followed-up hsCRP, was higher than that in the lowest quartile (all p<0.05). However, other components except for de novo PCI in the highest quartile by achieved LDL-C was not different to that in the lowest quartile. These results suggest that followed-up hsCRP can be more useful for predicting future cardiovascular outcome than achieved LDL-C in PCI-naïve patients with statin therapy.

Sign in / Sign up

Export Citation Format

Share Document